Twist Bioscience (NASDAQ:TWST) Trading Up 9.5% – Still a Buy?

Twist Bioscience Co. (NASDAQ:TWST) shares traded up 9.5% during trading on Wednesday . The stock traded as high as $46.91 and last traded at $46.81. 123,251 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 617,160 shares. The stock had previously closed at $42.75.

Analyst Ratings Changes

Several analysts have commented on the company. Barclays dropped their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. TD Cowen reaffirmed a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. Leerink Partners lifted their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Evercore ISI lifted their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Wolfe Research assumed coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $51.90.

Twist Bioscience Price Performance

The stock has a 50 day simple moving average of $46.43 and a two-hundred day simple moving average of $46.32. The company has a market cap of $2.72 billion, a price-to-earnings ratio of -12.74 and a beta of 1.85.

Insiders Place Their Bets

In other Twist Bioscience news, SVP Paula Green sold 1,057 shares of Twist Bioscience stock in a transaction on Monday, November 4th. The stock was sold at an average price of $41.56, for a total value of $43,928.92. Following the sale, the senior vice president now owns 121,013 shares in the company, valued at $5,029,300.28. The trade was a 0.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dennis Cho sold 659 shares of Twist Bioscience stock in a transaction on Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $27,388.04. Following the completion of the sale, the insider now owns 94,481 shares in the company, valued at $3,926,630.36. This represents a 0.69 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 89,640 shares of company stock valued at $4,123,772. Insiders own 3.01% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Signaturefd LLC raised its position in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Twist Bioscience by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock valued at $457,000 after buying an additional 312 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Twist Bioscience by 2.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock valued at $734,000 after buying an additional 363 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after buying an additional 381 shares during the period. Finally, D.A. Davidson & CO. raised its holdings in shares of Twist Bioscience by 3.5% in the 3rd quarter. D.A. Davidson & CO. now owns 19,618 shares of the company’s stock valued at $886,000 after buying an additional 664 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.